Amyris, Inc. (NASDAQ: AMRS) is a leading provider of bioscience solutions that cater to several industries such as health and wellness, clean beauty, and flavor and fragrance markets. Founded in 2003 by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger, Amyris has steadily built up its business over the years to become a well-respected player in the field.
Despite the company’s strong position, its stock has generated mixed responses from analysts. According to Bloomberg.com, eleven analysts have been keeping track of Amyris’ performance and have given it an overall “Hold” rating. Of these analysts, five have opted for a “hold” rating while one analyst recommended a “buy” rating. One analyst remains bearish on the stock with a “sell” rating.
Considering these ratings, coupled with recent developments in shareholder activity involving institutional investors buying and selling shares of AMRS stock–it’s clear that Amyris is receiving mixed attention from market participants.
Williams Jones Wealth Management LLC recently invested $45K into Amyris earlier this year. Meanwhile, FCA Corp TX invested $48K into AMRS for their first ever position in April 2021. Arete Wealth Advisors LLC had been more bullish on the company with investments worth around $15billion; however there is little information about how they feel about their investment currently.
On the other hand, Metropolitan Life Insurance Co NY bought up an additional 6,238 shares during Q3 which equated to around $35k worth of stock according to their public disclosures.end{verbatim}
Lastly, Atom Investors LP also made strategic purchases of AMRS during Q3 amounting roughly around $37K worth of stock value at current valuation.
Looking forward at the average 12 month price target among brokerages who have issued report within last year which stands at $3.06 per share- Investors may need to watch closely to see whether AMRS manages to continue impressing the markets. While this prediction is a nuanced process, investors will remain confident that Amyris may be on track for sustained growth.
In summary, it’s clear that Amyris has made significant strides in the provision of bioscience solutions despite variability of mixed analyst recommendations and shareholder activity lately. With its diverse range of products and commitment to innovative research, it’s safe to say that Amyris has much potential and investors should keep an eye on this dynamic company.
[bs_forecast_slider ticker=”AMRS”]
Amyris Stock Struggles as Multiple Brokerages Lower Price Targets and Issue ‘Sell’ Ratings
Amyris’s stock has had a rough few months, with multiple brokerages dropping their price targets and issuing “sell” ratings for the company. HC Wainwright dropped the target from $22 to $5 in March, while Piper Sandler lowered it from $1.50 to $1 a month later. StockNews.com began coverage of the company in mid-March and gave them a “sell” rating. Canaccord Genuity Group, however, saw potential and issued a buy rating with a price objective of $1.50 at the end of April.
Most recently, Jefferies Financial Group downgraded Amyris from a “buy” to a “hold,” citing concerns about performance and decreasing their price objective from $3.10 to just $0.65.
In addition to these obstacles, COO Eduardo Alvarez sold over 231,000 shares in early April at an average price of $1.23 per share.
Despite all this negativity, Amyris remains committed to providing bioscience solutions for industries like health and wellness, clean beauty, and flavor/fragrance markets since its founding in 2003 by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger.
However, the reality is that its stock opened at only $0.71 on Tuesday while having a one year low of just $0.55 after failing to meet analysts’ expectations for revenue during Q1 2021 in March even though it managed to generate around $75 million
While it is hard to ignore the signals sent by the current state of affairs surrounding Amyris Inc., some investors might prefer holding onto their investments given that experts anticipate that Amyris will post -0.57 earnings per share for the current fiscal year as well as seeing potential in it as seen by Canaccord Genuity Group’s buy rating with a price objective of $1.50.
